What is the 13F Pro Quality Score for VTAK?

13F Pro ranks Catheter Precision, Inc. (VTAK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VTAK's current score at https://13fpro.ai/research/VTAK (free sign-up required for the full ranking).

Where does 13F Pro source VTAK data?

All Catheter Precision, Inc. fundamentals and ownership data come directly from SEC EDGAR. Catheter Precision, Inc. files with the SEC under CIK 1716621. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VTAK in?

Catheter Precision, Inc. (VTAK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VTAK research updated on 13F Pro?

VTAK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Catheter Precision, Inc.(VTAK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1716621 VTAK stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $7.2M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

VTAK Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Catheter Precision, Inc. (VTAK), a Healthcare sector company. VTAK is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $7.2m in revenue. Based on the latest XBRL financial filings (Q1 2026), Catheter Precision, Inc. reports quarterly revenue of $432.0K, net income of $-1.7M, free cash flow of $-2.8M. Top institutional holders of VTAK by reported 13-F value include GEODE CAPITAL MANAGEMENT,, MILLENNIUM MANAGEMENT, JANE STREET GROUP,, based on the most recent SEC filings. VTAK trades on the NYSE exchange and files with the SEC under CIK 1716621. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTAK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Catheter Precision, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$432.0K

Net Income

Q1 2026

$-1.7M

Free Cash Flow

Q1 2026

$-2.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+95.0% YoY

$819.0KFY 2025

FY22 $14.0KFY23 $442.0KFY24 $420.0KFY25 $819.0K

Net Income

-3.2% YoY

$-17.2MFY 2025

FY22 $-26.9MFY23 $-70.6MFY24 $-16.6MFY25 $-17.2M

Operating Income

-88.1% YoY

$-21.1MFY 2025

FY22 $-27.0MFY23 $-78.1MFY24 $-11.2MFY25 $-21.1M

EPS (Diluted)

—FY 2025

FY22 $-25.98FY23 —FY24 —FY25 —

Total Assets

-42.9% YoY

$15.9MFY 2025

FY22 $16.8MFY23 $30.7MFY24 $27.8MFY25 $15.9M

Total Debt

$3.1MFY 2025

FY22 —FY23 —FY24 —FY25 $3.1M

Op. Cash Flow

+10.5% YoY

$-8.3MFY 2025

FY22 $-22.6MFY23 $-20.6MFY24 $-9.3MFY25 $-8.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$819.0K +95.0%	$420.0K -5.0%	$442.0K +3057.1%	$14.0K -99.7%	$4.4M -38.8%	$7.2M
Net Income	$-17.2M -3.2%	$-16.6M +76.4%	$-70.6M -162.7%	$-26.9M +25.5%	$-36.0M +36.7%	$-57.0M
Operating Income	$-21.1M -88.1%	$-11.2M +85.6%	$-78.1M -189.7%	$-27.0M +23.8%	$-35.4M +38.7%	$-57.7M
EPS (Diluted)	—	—	—	$-25.98	—	—
Total Assets	$15.9M -42.9%	$27.8M -9.6%	$30.7M +82.6%	$16.8M -49.7%	$33.4M -24.1%	$44.1M
Total Debt	$3.1M	—	—	—	—	$558.0K
Operating Cash Flow	$-8.3M +10.5%	$-9.3M +55.0%	$-20.6M +8.6%	$-22.6M +20.3%	$-28.3M +14.8%	$-33.2M

AI Insight: VTAK Financial Trends

Pre-revenue biotech burning cash with deteriorating leverage as debt surged 233% over the past year.

• Revenue remains zero across all eight quarters. Net losses averaged $4M quarterly with no clear improvement trajectory.

• Total debt jumped from $0M in Q2 2024 to $7M by Q1 2026, signaling reliance on financing to fund operations.

• Equity eroded 29% from $14M to $10M over two years, compressing financial cushion as burn continues.

⚠ Operating loss widened to $10M in Q4 2025, worst quarter on record; recent Q1 2026 recovery to $2M loss needs confirmation.

⚠ Debt-to-equity ratio deteriorated sharply to 0.70x in Q1 2026 from near-zero; unsustainable cash burn may force dilutive financing.

AI Insight: VTAK Ratio Trends

Cathay Precision remains deeply unprofitable, but ROA and ROE are trending sharply better—from -81.1% and -191.5% in Q4 2024 to -19.2% and -70.3% in Q1 2026.

• ROA improved 61.9 pp from Q4 2024 (-81.1%) to Q1 2026 (-19.2%), suggesting operational efficiency gains.

• ROE recovered 121.2 pp from Q4 2024 (-191.5%) to Q1 2026 (-70.3%), though still deeply negative.

• Leverage (D/E) rose from 0.22 in Q2 2025 to 0.68 in latest quarter, erasing prior deleveraging progress.

⚠ Company remains unprofitable across all metrics; negative ROE/ROA/ROIC in Q1 2026 signal ongoing cash burn.

⚠ Operating and net profit margins missing from all periods; cannot assess core business health independently.

Get alerted when VTAK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Catheter Precision, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VTAK

GEODE CAPITAL MANAGEMENT, LLC
$48.1K47,659 sh
MILLENNIUM MANAGEMENT LLC
$13.3K13,137 sh
JANE STREET GROUP, LLC
$11.5K11,379 sh
Tower Research Capital LLC (TRC)
$3.9K3,894 sh
UBS Group AG
$767.00759 sh
Allworth Financial LP
$303.00300 sh
Virtu Financial LLC
$14.0013,472 sh
Purpose Unlimited Inc.
$13.0013 sh
HRT FINANCIAL LP
$11.0011,276 sh
HARBOUR INVESTMENTS, INC.
$8.008 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$48.1K	47,659
MILLENNIUM MANAGEMENT LLC	$13.3K	13,137
JANE STREET GROUP, LLC	$11.5K	11,379
Tower Research Capital LLC (TRC)	$3.9K	3,894
UBS Group AG	$767.00	759
Allworth Financial LP	$303.00	300
Virtu Financial LLC	$14.00	13,472
Purpose Unlimited Inc.	$13.00	13
HRT FINANCIAL LP	$11.00	11,276
HARBOUR INVESTMENTS, INC.	$8.00	8

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VTAK on your watchlist

Track score changes the day Catheter Precision, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VTAK a good stock to buy?

13F Pro's AI-powered analysis of Catheter Precision, Inc. (VTAK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VTAK are available on the VTAK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VTAK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VTAK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Catheter Precision, Inc.'s investment landscape.